Ranibizumab Injections, Implants and Biosimilars
Customize your policy alerts
Sign up for healthspring Policy OTH903.041 alerts
Get alerted when Policy OTH903.041 changes without checking for updates manually.
Monitor payer policy activity
This policy governs medical-necessity coverage for intravitreal ranibizumab products, including Lucentis, biosimilars, and Susvimo administered through the Susvimo ocular implant. It applies to individuals receiving these ophthalmic treatments for specified retinal and ocular conditions.
The policy added ranibizumab-leyk (Nufymco) as a biosimilar and interchangeable product with Lucentis.
The policy added ranibizumab-hkdz (Ranluspec) as a biosimilar to Lucentis.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.